Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb;237(2):1143-1156.
doi: 10.1002/jcp.30615. Epub 2021 Oct 26.

Amphiregulin in cellular physiology, health, and disease: Potential use as a biomarker and therapeutic target

Siddharth S Singh  1 , Shashi B Chauhan  1 , Awnish Kumar  2 , Shashi Kumar  1 , Christian R Engwerda  3 , Shyam Sundar  1 , Rajiv Kumar  2
Affiliations
Review

Amphiregulin in cellular physiology, health, and disease: Potential use as a biomarker and therapeutic target

Siddharth S Singh et al. J Cell Physiol. 2022 Feb.

Abstract

Amphiregulin (AREG), which acts as one of the ligands for epidermal receptor growth factor receptor (EGFR), plays a crucial role in tissue repair, inflammation, and immunity. AREG is synthesized as membrane-anchored pre-protein, and is excreted after proteolytic cleavage, and serves as an autocrine or paracrine factor. After engagement with the EGFR, AREG triggers a cascade of signaling events required for many cellular physiological processes including metabolism, cell cycle, and proliferation. Under different inflammatory and pathogenic conditions, AREG is expressed by various activated immune cells that orchestrate both tolerance and host resistance mechanisms. Several factors including xenobiotics, cytokines, and inflammatory lipids have been shown to trigger AREG gene expression and release. In this review, we discuss the structure, function, and regulation of AREG, its role in tissue repair, inflammation, and homeostasis as well as the potential of AREG as a biomarker and therapeutic target.

Keywords: amphiregulin; biomarker; host resistance; inflammation; therapeutic targets.

PubMed Disclaimer

References

REFERENCES

    1. Adam, R., Drummond, D. R., Solic, N., Holt, S. J., Sharma, R. P., Chamberlin, S. G., & Davies, D. E. (1995). Modulation of the receptor binding affinity of amphiregulin by modification of its carboxyl terminal tail. Biochimica et Biophysica Acta/General Subjects, 1266(1), 83-90. https://doi.org/10.1016/0167-4889(94)00224-3
    1. Addison, C. L., Ding, K., Zhao, H., Le Maître, A., Goss, G. D., Seymour, L., Tsao, M. S., Shepherd, F. A., & Bradbury, P. A. (2010). Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21. Journal of Clinical Oncology, 28(36), 5247-5256. https://doi.org/10.1200/JCO.2010.31.0805
    1. Adib-Conquy, M., Pedron, T., Petit-Bertron, A. F., Tabary, O., Corvol, H., Jacquot, J., Clément, A., & Cavaillon, J. M. (2008). Neutrophils in cystic fibrosis display a distinct gene expression pattern. Molecular Medicine, 14(1-2), 36-44. https://doi.org/10.2119/2007-00081.Adib-Conquy
    1. Aguiari, G., Bizzarri, F., Bonon, A., Mangolini, A., Magri, E., Pedriali, M., Querzoli, P., Somlo, S., Harris, P. C., Catizone, L., & Del Senno, L. (2012). Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: Implications in ADPKD cell proliferation. J Mol Med (Berl), 90(11), 1267-1282. https://doi.org/10.1007/s00109-012-0902-3
    1. Amin, K., Yaqoob, U., Schultz, B., Vaughn, B. P., Khoruts, A., Howard, J. R., Defor, T. E., Forster, C., Meyer, C., Gandhi, I., Weisdorf, D. J., Rashidi, A., MacMillan, M. L., Blazar, B. R., Panoskaltsis-Mortari, A., & Holtan, S. G. (2019). Amphiregulin in intestinal acute graft-versus-host disease: A possible diagnostic and prognostic aid. Modern Pathology, 32(4), 560-567. https://doi.org/10.1038/s41379-018-0170-z

Publication types

LinkOut - more resources